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Background: Migraineurs are more often afflicted by comorbid conditions than those without primary headache
disorders, though the linking pathophysiological mechanism(s) is not known. We previously reported that
phosphatidylcholine-specific phospholipase C (PC-PLC) activity in cerebrospinal fluid (CSF) increased during
migraine compared to the same individual’s well state. Here, we examined whether PC-PLC activity from a larger
group of well-state migraineurs is related to the number of their migraine comorbidities.
Methods: In a case–control study, migraineurs were diagnosed using International Headache Society criteria, and
controls had no primary headache disorder or family history of migraine. Medication use, migraine frequency, and
physician-diagnosed comorbidities were recorded for all participants. Lumbar CSF was collected between the hours
of 1 and 5 pm, examined immediately for cells and total protein, and stored at −80°C. PC-PLC activity in thawed
CSF was measured using a fluorometric enzyme assay. Multivariable logistic regression was used to evaluate age,
gender, medication use, migraine frequency, personality scores, and comorbidities as potential predictors of PC-PLC
activity in CSF.
Results: A total of 18 migraineurs-without-aura and 17 controls participated. In a multivariable analysis, only the
number of comorbidities was related to PC-PLC activity in CSF, and only in migraineurs [parameter estimate
(standard error) = 1.77, p = 0.009].
Conclusion: PC-PLC activity in CSF increases with increasing number of comorbidities in migraine-without-aura.
These data support involvement of a common lipid signaling pathway in migraine and in the comorbid conditions.
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Migraineurs are prone to a large variety of comorbidities
[1]. Depression, the most common comorbid condition,
and migraine are among the highest ranked causes of global
years lived with disability [2]. Other comorbidities include
cardiovascular, respiratory, gastrointestinal, neurological,
and psychiatric conditions as well as osteoarthritis and
allergies [3-6]. Recent reports associated restless legs and
sensorineural hearing loss with migraine [7,8]. The mo-* Correspondence: afonteh@hmri.org; mghworks@hmri.org
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in any medium, provided the original work is plecular associations that are common to these disorders
are not known, but include shared genetic risk factors
[6,9], regulation of brain cations [10], or common receptor
signaling events that activate pain [11], inflammatory [12],
or oxidative [13] pathways. The same neurotransmitter
acting at different sites may also underlie varied disorders;
for example, serotonin and endocannabinoids are impli-
cated in both depression and migraine [14,15].
To consider common biochemical pathways, migraine
and many of its comorbidities have been found to share al-
terations in serotonin [16], noradrenaline [17,18], estrogen
[19], cannabinoids [20,21], and glutamate [22,23]. Medica-
tions that modulate the G-protein coupled receptorsan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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graine and comorbidities [24,25]. Since the signaling path-
ways for these ligand-bound GPCRs involve PC-PLC
activation [26-28], we hypothesize that migraine and its
comorbidities share a common pathway of receptor-
mediated, lipid second-messengers that are regulated by
PLC activation. Migraine model studies further implicate
PLC pathway involvement: the migraine trigger pituitary
adenylate cyclase activating peptide-38 induced mast cell
degranulation in the rat dura mater, mediated by the PLC
pathway [29]; and a homolog of the familial hemiplegic
migraine candidate gene 2 in C. elegans (EAT-6) interacts
with a homolog (EGL-8) of PLC [30]. Similarly, newly
identified peptides such as orexin and ghrelin, which are
known to regulate sleep-wakefulness, mediate their excita-
tory effects on the pedunculopontine tegmental nucleus
by PLC activation [31].
We tested the hypothesis that migraine and its
comorbidities share a common receptor-mediated path-
way. We compared migraineurs and non-headache suf-
fering controls on the relationship between PC-PLC
activity in CSF and the number of different comor-
bidities experienced. Our hypothesis of PC-PLC dysre-
gulation predicts that a person with a more extensive
number of comorbid conditions would have greater de-
viation of PC-PLC activity within the nervous system,
and this would be reflected in the CSF.
Methods
This case–control study, conducted between 2004 and
2011, was designed to measure PC-PLC activity in lum-
bar CSF from migraineurs (cases) and non-headache suf-
fering controls and to associate it with the number of
physician diagnosed conditions known to be comorbid
with migraine. The Huntington Hospital Institutional
Review Board for Human Research approved the study
protocol and consent forms which all participants
signed.
Study participants
Consecutive participants between 18 and 75 years of age
were recruited from our research clinic and from the
Pasadena area through local advertising and research
presentations. All controls and migraineur participants
were recruited prospectively for this study to our re-
search institute. After informed consent was given, we
assessed them using structured interviews and by clinical
examination. Our goal was to recruit as many partici-
pants as possible over the time period. We excluded par-
ticipants with any contraindication for lumbar puncture
(e.g., warfarin) or with any additional, uncontrolled diag-
nosis identified from the assessments. They returned for
CSF collection within 2 weeks of completing clinical
assessment.Headache diagnosis was determined by consensus
after clinical assessment by one of two migraine diagnos-
ticians (RPC or MGH). To minimize heterogeneity,
migraineurs were included as cases only when the pri-
mary headache disorder was migraine-without-aura, as
defined by the criteria of the International Classification
for Headache Disorders, 2nd edition (ICHD-2 code 1.1).
Additional case inclusion criteria were: at least 1 mi-
graine per month and less than 15 headache days per
month; availability of data on duration of migraine and
attack frequency for the preceding year; all medications
recorded for 90 days before and throughout the study;
no change in prophylactic medications during the 90
days before study; and no rescue medication taken
within 48 hours of sample collection. Migraine fre-
quency for the preceding 12 months was recorded from
that estimated by each participant. Migraine intensity,
only used for diagnosis, was recorded from a subjective
0 – 10 scale, without treatment when available, for their
range of migraine at typical, mild, and most severe
episodes.
Inclusion criteria for healthy controls were: absence of
primary headache disorder after the same assessments as
migraineurs; no family history of migraine in first-degree
relatives; and no change in prophylactic medications for
90 days before and throughout the study.
Data collection
Comorbidities
Participants were required to complete an extensive
structured interview for medical and neurological disor-
ders and medical and neurological examinations to
document any other conditions, including comorbid
diagnosis. Body mass index (BMI) was calculated from
height and weight ascertained at study enrollment. The
Structured Clinical Interview for DSM-IV Axis I Disor-
ders, Research Version/Non-patient Edition, was admin-
istered to participants to evaluate major psychiatric
diagnosis (SCID-I) and the Axis II Disorders (SCID-II)
interview was administered to diagnose personality dis-
orders. We assessed personality in more detail using the
1989 revision of the Minnesota Multiphase Personality
Inventory (MMPI-2). We paid particular attention to the
first three clinical scales dealing with concern for bodily
symptoms that have been reported to differ in migraine
[32]: Scale 1 (Hypochondriasis), Scale 2 (Depression),
and Scale 3 (Hysteria). To determine subjective symptoms
and severity of depression, participants rated themselves
using the Beck Depression Inventory, 2nd edition (BDI-2)
[33]. Prior comorbidities were based on diagnosis by a spe-
cialist physician, independent of the migraine/control diag-
nosis by the research clinician: depression (psychiatrist),
anxiety (psychiatrist), epilepsy (neurologist), allergy (allergist
or internist), asthma (internist), eczema (dermatologist),
Fonteh et al. The Journal of Headache and Pain 2013, 14:60 Page 3 of 6
http://www.thejournalofheadacheandpain.com/content/14/1/60irritable bowel syndrome (gastroenterologist or internist),
fibromyalgia (rheumatologist or internist), patent foramen
ovale (cardiologist), mitral valve prolapse (cardiologist),
hypertension (internist or cardiologist), osteoarthritis
(rheumatologist or internist), and painful bladder syn-
drome (urologist).
Having a single investigator record assessment of
comorbidities throughout the study, and using a struc-
tured interview list to obtain responses to direct ques-
tions of physician-diagnosis for each known comorbid
condition controlled potential bias in the ascertainment
of comorbid diagnoses for all participants. It was not
practical for the investigator to be blind to case–control
status, as this status was usually described during the
assessment.
CSF
Migraineurs had no headache (0 of 0–10 scale) for > 24
hours at the time of CSF collection. All CSF samples
were collected between 1:00 and 6:00 pm to minimize
chronobiological variation. CSF was obtained by lumbar
puncture using a 22-gauge Quincke-type needle, cen-
trifuged (3000 g for 3 min) for cell count, and the super-
natant fluid was stored at −80° C until thawed for PC-
PLC or total protein assay. The same fraction of CSF
from three sequential fractions taken from each partici-
pant was analyzed in this study to reduce variation from
the neuraxis gradient.
Laboratory
Cells were counted in a hemocytometer with trypan blue
exclusion. Total protein concentrations were determined
with the fluorescent Quant-iT™ protein assay kit
(Invitrogen/Molecular Probes, Eugene, OR) with bovine
serum albumin (0–500 ng/ml) as a standard for quantifi-
cation. Fluorescence (excitation at 470 nm and emission
at 570 nm) was measured using a Gemini XPS Dual-
Scanning Microplate Spectrofluorometer and data ana-
lyzed using SoftMax® Pro software (Molecular Devices,
Sunnyvale, CA).
PC-PLC assay
Amplex® Red PC-PLC Assay Kit (A12218, Invitrogen/
Molecular Probes) was used to measure enzyme activity
in CSF. PC-PLC from Bacillus cereus was used as a posi-
tive control to estimate PLC protein content of CSF.
CSF was diluted in sample buffer (50 mM Tris–HCl
(pH 7.4), 0.14 M NaCl, 10 mM dimethylglutarate, 2 mM
CaCl2) to ~0.1 mg/ml, and placed in 96 well plates in trip-
licates. Adding 100 μl Amplex Red working solution to
100 μL of the diluted CSF samples started PLC activity.
The plate was incubated at 37°C with monitoring of fluor-
escence using excitation at 545 nm and emission detection
at 590 nm every 5 min for 90 min. An increase in fluores-cence due to PLC-induced release of phosphocholine
was recorded and specific activity calculated as Relative
Fluorescence Unit (RFU) per microgram protein per
min (RFU/mg/min).
Potential bias in the collection of PC-PLC activity
levels was controlled by randomly assigning samples
from migraineurs and controls to plates by a single in-
vestigator and by running and analyzing samples in
batches by a separate investigator who was blinded to
case–control status.
Statistical analysis
Complete data were obtained for all participants. Group
comparisons were done using Fisher’s exact tests for cat-
egorical variables and Wilcoxon rank sum or Student’s t
tests, as appropriate, for continuous variables. All ana-
lyses were univariable unless otherwise stated. Multivari-
able analyses, including computation of least squares
(LS) means and standard errors (SEs) were done using
general linear models [34]. Analyses were done using
SAS v9.2 (SAS Institute, Inc., Cary, NC). All tests were
two-sided with 0.05 significance levels.
Results
Clinical findings
A total of 35 study participants (17 controls and 18
migraineurs-without-aura) met study inclusion criteria
and consented to the study. All participants completed
the study without adverse effects from the lumbar punc-
ture. Table 1 describes the clinical characteristics, CSF cell
counts and total protein. Controls were older (p = 0.01)
and had a greater percentage of males (p = 0.15) than
migraineurs. As expected, controls took fewer prescription
medications (p = 0.0001) and, in contrast with some re-
ports [35], had higher BMI (p = 0.03) than migraineurs.
MMPI Scales 1–3 and BDI-2 scores were significantly
higher in migraineurs than in controls. None of the con-
trols or migraineurs had episodes of Axis I depression
within 3 months before assessment. CSF cell counts and
total proteins were within normal ranges in both controls
and migraineurs.
Frequencies of individual comorbidities are shown in
Table 2. Total number of comorbidities per participant
group was higher in migraineurs than controls, though
not significantly. Depression was twice as common in
the migraineurs.
CSF PC-PLC activity
Mean PC-PLC activity levels were similar in migraineurs
[mean (SD) = 9.79 (3.42) RFU/mg/min] and controls
[mean 9.29 (1.97) RFU/mg/min]. In a multivariable mo-
del with age and sex as independent variables, among
controls age was inversely related to PC-PLC (parameter
estimate (SE) = −0.045 (0.022), p = 0.054) and males had
Table 1 Clinical characteristics, cerebrospinal fluid (CSF) cell counts and total protein by diagnostic group
n Controls n Migraineurs P-value
Men, n (%) 7 (41) 3 (17) 0.15
Women, n (%) 10 (59) 15 (83)
Age (years), mean (SD) 17 62.1 (18.6) 18 46.9 (15.7) 0.01
Body mass index (kg/m2), mean (SD) 17 26.4 (3.4) 16 23.4 (4.1) 0.03
# Comorbidities, mean (SD) 17 1.6 (1.2) 18 1.9 (1.2) 0.47
# Medicines, mean (SD) 17 0.35 (0.49) 18 5.3 (4.4) 0.0001
MMPI Scale 1, mean (SD) 11 50.3 (7.8) 15 59.3 (9.0) 0.01
MMPI Scale 2, mean (SD) 11 47.3 (6.1) 16 56.0 (10.3) 0.01
MMPI Scale 3, mean (SD) 11 49.2 (5.9) 16 57.6 (14.0) 0.04
BDI-2, mean (SD) 14 3.9 (3.6) 17 8.5 (5.2) 0.009
CSF cell count 17 < 5 per mL 18 < 5 per mL
CSF total protein, g/L (SD) 17 0.36 (0.11) 18 0.36 (0.12) 0.78
MMPI Minnesota Multiphasic Personality Inventory, BDI-2 Beck Depression Inventory-2.
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males, 10.2 (0.50) females; p = 0.01); among migraineurs,
age was not related to PC-PLC activity (p = 0.99) and
the difference in LS means by sex was similar to that in
controls [LS mean (SE) = 7.6 (2.10) males, 10.2 (0.91) fe-
males], though non-significant (p = 0.28). Thus, the lack
of difference between migraineurs and controls in PC-
PLC was the same regardless of sex.
In a multivariable analysis of migraineurs that consid-
ered sex, number of medications used, migraine frequency
(days) in the past year, psychiatric measures, and number
of comorbidities as potential predictors of PC-PLC ac-
tivity, only number of comorbidities was independently
significantly related to PC-PLC (parameter estimate
(SE) = 1.77 (0.58), p = 0.009; Table 3). Only 2 migraineursTable 2 Number of comorbidities, diagnosed by a specialist,
by diagnostic group
Comorbidities Controls (n = 17) Migraineurs (n = 18)
Depression 5 (29%) 10 (56%)
Anxiety 0 1 (6%)
Epilepsy 1 (6%) 0
Hypertension 4 (24%) 3 (17%)
Irritable bowel syndrome 2 (12%) 3 (17%)
Mitral valve prolapse 1 (6%) 1 (6%)
Patent foramen ovale 1 (6%) 2 (11%)
Osteoarthritis 5 (29%) 6 (33%)
Painful bladder syndrome 1 (6%) 4 (22%)
Fibromyalgia 1 (6%) 1 (6%)
Asthma/allergy 3 (18%) 2 (11%)
Eczema 0 1 (6%)
Total 24 34had no comorbidities. With number of comorbidities di-
chotomized as 0–1 and > 1, PC-PLC did not differ by sex
among migraineurs in the 0–1 comorbidity group, and
there are no men in the > 1 comorbidity group.
In a multivariable analysis of controls that considered
the same potential predictors as above except migraine
frequency, only age and sex were significant independent
predictors.
Discussion
We observed that PC-PLC activity was positively corre-
lated with the number of comorbid conditions in
migraineurs but not in controls, supporting our hypoth-
esis that PC-PLC activity is part of a common pathway
in the comorbid conditions of migraineurs. This first de-
scription of a shared involvement of CSF PC-PLC in
these comorbid conditions is significant when it is con-
sidered that many helpful medications modulate the bio-
chemical pathways that also share involvement in these
conditions, such as serotonin [16] or noradrenaline
[17,18]. This inference raises the possibility that modula-
tors of PC-PLC may help lessen migraine, as well as
other comorbid conditions.
We also observed greater PC-PLC activity in CSF in
females in both migraineurs and controls and, among
controls only, in younger participants. Given theTable 3 CSF PC-PLC activity levels (RFU/mg/min) in







0 or 1 7 7.5 (1.5)
2 6 9.9 (3.8)
> 2 5 12.9 (2.7)
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controls, the sex difference we observed is consistent
with the higher incidence of migraine in the female
population.
In considering how PLC activity may relate to migraine
and its comorbidities, many of these distinct conditions
share a multifaceted pathophysiology, with alterations in
molecules as diverse as serotonin, adrenaline, estrogen,
cannabinoids, and glutamate, and include the activation of
several GPCRs, protein kinase mediated signaling, and
early gene activation (c-fos) [36,37]. PC-PLC plays a role
in this process by generating the protein kinase activator,
diacylglycerol, and affecting Ca2+ influx into cells [38,39].
We hypothesize that varying PC-PLC levels, as we ob-
served in our study, reflect fluctuations from their modu-
lation of many G protein coupled receptors, and that any
changes of PC-PLC activity in the brain are reflected in
CSF. Once altered, PC-PLC can have diverse effects. For
example, signaling pathways induced by PC-PLC can form
inflammatory or pain molecules; also, PC-PLC can
hydrolyze PC, a major component of membrane lipids, al-
tering membrane properties and the functions of ion
channels imbedded in the lipid bilayer [40]. Our data sug-
gest that the diverse pain, inflammatory, and behavioral
features common to migraine and its comorbidities may
arise at least partially from altered PC-PLC activity. Many
different CSF PLC isoforms are yet to be defined, but their
roles in vascular endothelial dysfunction and inflammation
can be explored for therapy [41]. Thus, future studies of
isoform-specific PLC modulation may lead to treatments
for migraine and its comorbid conditions.
The invasiveness of collecting lumbar CSF in a pro-
spective study led to a relatively small study population
(n = 35) and interpreting results from a multivariable
analysis can lead to not only bias but to under- or over-
estimated variance; this, combined with the clinical dif-
ferences we observed between controls and migraineurs
(such as differences in medication use), necessitates cau-
tious interpretation of our findings. For example, the
small numbers for each individual comorbidity (Table 2)
means we were unable to analyze the CSF PC-PLC ac-
tivity levels for any individual comorbidity or to fully
explore possible confounders and modifiers of the as-
sociation between PC-PLC activity and comorbidities.
We used physician-diagnosed comorbidities which
probably underrepresent some diagnoses; however, this
should have occurred randomly in both migraineurs
and controls and without regard for PC-PLC activity
levels, likely leading to attenuated estimates of the rela-
tionships between migraine, comorbidities, and PC-
PLC activity. Furthermore, using physician-diagnosed
comorbidities minimized the potential bias associated
with unblinded participant interviews to ascertain med-
ical histories.Conclusions
We report that the PC-PLC activity in CSF from partici-
pants with migraine-without-aura, but not for non-
headache suffering controls, increases in proportion to
the number of migraine comorbidities. These findings
offer the potential insight of PC-PLC signaling as a com-
mon pathway in migraine and its comorbidities.
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